US 11,857,574 B2
Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
Mary-Lee Dequeant, Cambridge, MA (US); Demetrios Kalaitzidis, Cambridge, MA (US); and Mohammed Ghonime, Cambridge, MA (US)
Assigned to CRISPR Therapeutics AG, Zug (CH)
Filed by CRISPR Therapeutics AG, Zug (CH)
Filed on Nov. 10, 2022, as Appl. No. 18/054,521.
Application 18/054,521 is a continuation of application No. 17/493,280, filed on Oct. 4, 2021, granted, now 11,497,773.
Application 17/493,280 is a continuation of application No. 17/483,100, filed on Sep. 23, 2021.
Claims priority of provisional application 63/225,673, filed on Jul. 26, 2021.
Claims priority of provisional application 63/124,429, filed on Dec. 11, 2020.
Claims priority of provisional application 63/082,357, filed on Sep. 23, 2020.
Prior Publication US 2023/0263828 A1, Aug. 24, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/17 (2015.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01); C12N 9/22 (2006.01); C12N 15/01 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/16 (2006.01); C12N 15/113 (2010.01); C12N 15/86 (2006.01); A61K 38/00 (2006.01); C12N 15/11 (2006.01)
CPC A61K 35/17 (2013.01) [C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70575 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 16/2803 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); C12N 5/0636 (2013.01); C12N 5/16 (2013.01); C12N 9/22 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); C07K 2317/622 (2013.01); C12N 2310/20 (2017.05); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2510/00 (2013.01)] 21 Claims
 
1. A population of immune cells, which comprises genetically engineered T cells, wherein the genetically engineered T cells comprise:
(i) a disrupted Regnase-1 (Reg1) gene;
(ii) a disrupted Transforming Growth Factor Beta Receptor II (TGFBRII) gene; and
(iii) a nucleic acid encoding a chimeric antigen receptor (CAR) that binds a tumor antigen.